Heuszel Frank D

CEO Frank D Heuszel bought 500 IBO shares at $2.26 on 2024-12-05; third purchase in 9 days amid -24.8% 30-day decline.

CEO Frank D Heuszel purchased 500 shares at $2.26, bringing his holdings to 97,344 shares post-transaction. This marks his third open-market buy in 9 days (prior purchases on 2024-11-27, 2024-11-26, and 2024-11-26), during a period when IBO's stock has declined 24.8% over the past 30 days and trades 28.3% below its 52-week high of $3.04. The company's fundamentals are mixed: while the latest quarter shows net income of $4,241,000.00, the company was unprofitable over its most recent full fiscal year, and quarterly revenue stands at $50,000.00. The concentrated buying pattern in early December warrants attention as an indicator of insider activity during price weakness, though the recency of all three purchases prevents 90-day outcome assessment.

CEO Frank D Heuszel bought 1,050 shares at blended average price of $2.61 on 2024-11-26.

Frank D Heuszel, CEO of Impact Biomedical, purchased 1,050 shares across 2 separate transactions (550 shares at $2.62 and 500 shares at $2.59) for a combined $2,738.75, increasing his holdings to 96,344 shares. The purchase occurred when the stock was trading at a 24.3% discount to its 52-week high and down 14.2% over the prior 30 days, suggesting the CEO acquired shares during a period of price weakness relative to recent history. However, Impact Biomedical reported a negative full-year net income despite current-quarter profitability ($4.2M quarterly net income), and the company's market cap of $26,459,096.50 with P/E of 23.00 indicates elevated valuation relative to its size and profitability trajectory. The magnitude of this purchase (1.1% addition to holdings) is modest against the CEO's existing 96.3K-share position, and his cross-ticker track record shows only 1 prior buy with no measurable timing outcomes yet available for evaluation.

CEO Frank D Heuszel bought 500 shares at $2.61 on 2024-11-27, second consecutive day purchase; stock -24.3% from 52-week high.

Frank D Heuszel, Chief Executive Officer of Impact Biomedical Inc., purchased 500 shares at $2.61 on 2024-11-27, following another purchase of 30 shares at the same price on 2024-11-26. The stock is currently trading at $2.30, down -24.3% from its 52-week high and down 30-day change: -14.2%. While the company reported a net income of $4.2M against revenue of $50.0K in the latest quarter (P/E of 23.00), it was unprofitable over its most recent full fiscal year. The total value of this transaction was $1,305.00 ($1.3K), representing a modest 0.5% increase to his holdings from 96.3K to 96.8K shares. Heuszel's cross-ticker track record shows only 2 prior buys, with insufficient measurable history at this specific ticker to establish a timing pattern.